DSKYF: AI 评分 55/100 — AI 分析 (4月 2026)

Daiichi Sankyo Company, Limited is a global pharmaceutical company focused on researching, developing, and commercializing innovative medicines. With a history dating back to 1899, the company has a diverse portfolio of products across various therapeutic areas.

Key Facts: AI Score: 55/100 Sector: Healthcare

公司概况

概要：

Daiichi Sankyo Company, Limited, a Japanese pharmaceutical company, develops and markets a diverse range of drugs including oncology treatments, cardiovascular medications, and vaccines. With a global presence and a focus on innovative therapies like antibody drug conjugates, Daiichi Sankyo maintains a significant position in the competitive pharmaceutical landscape.

DSKYF是做什么的？

Founded in 1899 and headquartered in Tokyo, Japan, Daiichi Sankyo Company, Limited is a global pharmaceutical organization dedicated to creating and supplying innovative pharmaceutical products. The company's operations span research and development, manufacturing, marketing, and sales of pharmaceuticals across the world. Daiichi Sankyo's product portfolio includes treatments in oncology, cardiovascular disease, pain management, and other therapeutic areas. Key products include trastuzumab deruxtecan (Enhertu), an anti-cancer agent, mirogabalin for pain, and edoxaban, an anticoagulant. The company also offers treatments for diabetes, osteoporosis, and various infectious diseases. Daiichi Sankyo has a significant presence in both developed and emerging markets. The company emphasizes research and development, particularly in oncology, and collaborates with other organizations to advance its pipeline. A collaboration with Guardant Health focuses on developing Guardant360 CDx as a companion diagnostic for Enhertu in non-small cell lung cancer. Daiichi Sankyo's long history and diverse product range contribute to its established position in the pharmaceutical industry.

DSKYF的投资论点是什么？

Daiichi Sankyo presents a compelling investment case based on its established position in the pharmaceutical industry, diverse product portfolio, and focus on innovative therapies. The company's oncology franchise, particularly Enhertu, is a key growth driver. With a P/E ratio of 17.85 and a profit margin of 14.8%, Daiichi Sankyo demonstrates financial stability. The company's dividend yield of 2.35% offers an additional incentive for investors. Upcoming catalysts include potential regulatory approvals for new indications of existing drugs and advancements in its research and development pipeline. However, potential risks include competition from other pharmaceutical companies and regulatory challenges. The company's beta of -0.30 suggests lower volatility compared to the overall market.

DSKYF在哪个行业运营？

Daiichi Sankyo operates in the global pharmaceutical industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The industry is driven by innovation, with companies constantly seeking to develop new and improved treatments for various diseases. The market for oncology drugs is particularly competitive and lucrative. Daiichi Sankyo's focus on antibody drug conjugates positions it well within this landscape. The company competes with other major pharmaceutical companies, including CHALF, HLNCF, HOCPF, IPSEY, and OTSKY, all vying for market share in key therapeutic areas.

Drug Manufacturers - General

Healthcare

DSKYF有哪些增长机遇？

Expansion of Enhertu: Enhertu, Daiichi Sankyo's anti-HER2 antibody drug conjugate, presents a substantial growth opportunity. The global market for HER2-positive breast cancer therapies is significant, and Enhertu's efficacy has positioned it as a leading treatment option. Further expansion into other HER2-expressing cancers, such as non-small cell lung cancer, could significantly increase its market potential. The collaboration with Guardant Health to develop companion diagnostics will further enhance Enhertu's adoption and effectiveness. Timeline: Ongoing.
Development of New Oncology Therapies: Daiichi Sankyo's commitment to oncology research and development provides a strong foundation for future growth. The company's pipeline includes several promising new cancer therapies targeting various mechanisms of action. Successful development and commercialization of these therapies could drive significant revenue growth and strengthen Daiichi Sankyo's position in the oncology market. The global oncology market is projected to reach $300 billion by 2025. Timeline: Ongoing.
Geographic Expansion: Expanding into emerging markets represents a significant growth opportunity for Daiichi Sankyo. These markets, with their growing populations and increasing healthcare spending, offer substantial potential for pharmaceutical sales. Establishing a strong presence in these regions could diversify Daiichi Sankyo's revenue streams and reduce its reliance on developed markets. Key emerging markets include China, India, and Brazil. Timeline: Ongoing.
Strategic Partnerships and Acquisitions: Forming strategic partnerships and acquiring complementary businesses can accelerate Daiichi Sankyo's growth. Collaborations with biotechnology companies and research institutions can provide access to innovative technologies and drug candidates. Acquisitions can expand Daiichi Sankyo's product portfolio and geographic reach. The pharmaceutical industry is characterized by frequent mergers and acquisitions. Timeline: Ongoing.
Advancements in Pain Management Therapies: Daiichi Sankyo's mirogabalin, a novel pain medication, addresses a significant unmet need in the treatment of neuropathic pain. The global pain management market is substantial, and effective new therapies are in high demand. Expanding the indications for mirogabalin and developing other pain management products could drive significant growth in this therapeutic area. The global pain management market is projected to reach $90 billion by 2027. Timeline: Ongoing.

Market Cap of $32.32B reflects Daiichi Sankyo's significant size and established position in the pharmaceutical industry.
P/E Ratio of 17.85 indicates the company's valuation relative to its earnings.
Profit Margin of 14.8% demonstrates the company's ability to generate profit from its revenue.
Gross Margin of 77.5% showcases the efficiency of Daiichi Sankyo's operations and the value of its products.
Dividend Yield of 2.35% provides investors with a steady income stream.

DSKYF提供哪些产品和服务？

Researches and develops pharmaceutical products.
Manufactures pharmaceutical products.
Imports pharmaceutical products.
Markets pharmaceutical products.
Sells pharmaceutical products.
Offers treatments for oncology, cardiovascular diseases, pain management, and other therapeutic areas.
Provides vaccines for various infectious diseases.

DSKYF如何赚钱？

Develops and patents innovative pharmaceutical products.
Conducts clinical trials to demonstrate the safety and efficacy of its products.
Obtains regulatory approvals from agencies such as the FDA and EMA.
Manufactures and distributes its products globally.
Markets and sells its products through a network of sales representatives and distributors.

Hospitals and clinics
Pharmacies
Healthcare providers
Patients
Government healthcare agencies

Patents and intellectual property protection for its innovative drugs.
Strong brand reputation and established relationships with healthcare providers.
Extensive research and development capabilities.
Global distribution network.
Regulatory expertise and experience.

什么因素可能推动DSKYF股价上涨？

Ongoing: Potential regulatory approvals for new indications of existing drugs.
Ongoing: Advancements in the research and development pipeline, particularly in oncology.
Ongoing: Expansion into emerging markets.
Ongoing: Strategic partnerships and acquisitions.
Ongoing: Growth in the oncology market.

DSKYF的主要风险是什么？

Potential: Intense competition from other pharmaceutical companies.
Potential: Patent expirations.
Potential: Regulatory challenges.
Potential: Economic downturns.
Ongoing: Reliance on a limited number of key products.

DSKYF的核心优势是什么？

Strong oncology pipeline with promising new therapies.
Established presence in key therapeutic areas.
Global distribution network.
Experienced management team.

DSKYF的劣势是什么？

Reliance on a limited number of key products.
Exposure to generic competition.
High research and development costs.
Dependence on regulatory approvals.

DSKYF有哪些机遇？

Expansion into emerging markets.
Strategic partnerships and acquisitions.
Development of new therapies for unmet medical needs.
Growth in the oncology market.

DSKYF面临哪些威胁？

Intense competition from other pharmaceutical companies.
Patent expirations.
Regulatory challenges.
Economic downturns.

DSKYF的竞争对手是谁？

Chiesi Farmaceutici S.p.A. — Focuses on respiratory and specialty care. — (CHALF)
H Lundbeck A/S — Specializes in neurological and psychiatric disorders. — (HLNCF)
Hospira Inc — Focuses on generic injectable pharmaceuticals and infusion technologies. — (HOCPF)
Ipsen SA — Develops specialty care pharmaceuticals. — (IPSEY)
Otsuka Holdings Co., Ltd. — Offers a diverse portfolio of pharmaceutical and consumer products. — (OTSKY)

Key Metrics

MoonshotScore: 55/100

Company Profile

CEO: Hiroyuki Okuzawa
Headquarters: Tokyo, JP
Employees: 18,726
Founded: 2008

AI Insight

AI analysis pending for DSKYF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Daiichi Sankyo Company, Limited do?

Daiichi Sankyo Company, Limited is a global pharmaceutical company involved in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Its portfolio includes treatments for various therapeutic areas, including oncology, cardiovascular diseases, and pain management. The company's key products include trastuzumab deruxtecan (Enhertu), mirogabalin, and edoxaban. Daiichi Sankyo operates globally, serving hospitals, clinics, pharmacies, and patients through its network of sales representatives and distributors. The company focuses on innovation and strategic partnerships to drive growth and address unmet medical needs.

What do analysts say about DSKYF stock?

Analyst consensus on DSKYF stock is currently unavailable. Key valuation metrics to consider include the company's P/E ratio of 17.85 and its dividend yield of 2.35%. Growth considerations include the potential for Enhertu and other pipeline drugs, as well as expansion into emerging markets. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions. Further AI analysis is pending.

What are the main risks for DSKYF?

The main risks for Daiichi Sankyo include intense competition from other pharmaceutical companies, patent expirations, regulatory challenges, and economic downturns. The company also faces risks associated with its reliance on a limited number of key products. Generic competition could erode sales of established drugs. Regulatory setbacks could delay or prevent the approval of new therapies. Economic downturns could reduce healthcare spending and negatively impact sales. Investors should carefully consider these risks before investing in DSKYF.